Navigation Links
3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer

SHENYANG, China, March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) (''3SBio'' or the ''Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio.

Since joining 3SBio in June 2007, Dr. Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr. Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China.

Dr. Jing Lou, CEO of 3SBio, commented, ''I am very pleased to announce the promotion of David Chen to the position of Chief Operating Officer. Since assuming the role of VP of Business Development, David has quickly demonstrated his leadership skills and has played a critical role in planning and executing our future growth strategies and partnering initiatives, helping to establish relationships with a number of potential partners around the world. His in-depth understanding of the Chinese pharmaceutical market place combined with his significant operating experience with multinational pharmaceutical companies in the US make him the ideal candidate to assume this newly created position. I look forward to working together with David as we help drive the next phase of 3SBio's growth.''

Prior to joining 3SBio, Dr. Chen, 42, held various managerial positions in the US pharmaceutical industry, including business development, sales and marketing, market research, new product development and R&D portfolio management both with Eli Lilly and GlaxoSmithKline. Prior to his experience in the US, Dr. Chen was a practicing orthopedic surgeon at Shanghai Medical University from 1989 to 1992. He received a medical degree from the First Military Medical University in Guangzhou, China, and earned a Masters Degree in Business Administration from the Darden School of Business at the University of Virginia.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at .

For more information, please contact:

Investor Contact:

Kevin Teo, CFO

3SBio Inc.

Tel: +86-24-2581-1820


Investor Relations(HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712


Investor Relations(US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350


Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
2. 3SBio Inc. Announces Change to the Board of Directors
3. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
4. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
7. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
8. 3SBio Inc. to Hold Annual General Meeting
9. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL database ... maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide a ...
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
Breaking Biology Technology:
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
Breaking Biology News(10 mins):